Radiation Dermatitis - Prevention and Skin Care

Key Points

• Gentle washing is encouraged during radiation; keeping the field unwashed is outdated advice.
• Use fragrance-free moisturizers and minimize friction and trauma.
• Topical corticosteroids can reduce acute dermatitis severity in selected patients.
• Barrier films have evidence and MASCC guidance for selected treatment sites.
• Skin tone affects how erythema appears; symptoms and texture matter for grading.
• Moist desquamation should be managed as a wound with nonadherent moisture-balancing dressings.
• Routine systemic antibiotics are not indicated without evidence of infection.
• Treatment breaks are avoided when possible because prolonged overall treatment can reduce cancer-control efficacy in some settings.
• Peak dermatitis can occur shortly after radiation finishes.
• Persistent ulceration or severe atypical injury needs specialist reassessment.

Algorithm

1. Assess baseline skin integrity, folds, prior surgery, lymphedema, and expected skin dose.
2. Begin gentle washing, moisturizer, friction reduction, and sun protection from treatment start.
3. Consider prophylactic topical corticosteroid according to site-specific protocol.
4. Consider barrier film in an appropriate breast or head-and-neck treatment workflow.
5. Grade skin weekly using symptoms and physical findings rather than erythema alone.
6. For dry dermatitis, intensify moisturization and anti-inflammatory symptom control.
7. For moist desquamation, use wound-care dressings and adequate analgesia.
8. Evaluate fever, purulence, expanding erythema, or unexpected deterioration for infection.
9. Avoid unnecessary treatment interruptions; involve radiation oncology for grade 3 or greater toxicity.
10. Continue skin care after completion until re-epithelialization occurs.

Clinical Synopsis & Reasoning

Radiation dermatitis develops because ionizing radiation injures basal keratinocytes, microvasculature, hair follicles, and inflammatory pathways. Reactions typically begin after one to several weeks of fractionated treatment and intensify with cumulative dose. Erythema and dry desquamation can progress to tender moist desquamation in skin folds or high-dose regions. Symptoms include burning, pruritus, pain, tightness, and impaired sleep. Severe ulceration or necrosis is uncommon with contemporary planned treatment and should prompt review for excessive dose, infection, tumor involvement, or unusual radiosensitivity.

Risk depends on treatment and patient factors. Higher skin dose, bolus, large fields, breast or head-and-neck folds, concurrent chemotherapy, friction, obesity, smoking, and some targeted therapies can increase severity. Skin reactions after proton therapy or highly conformal techniques depend on entrance and surface dose distribution. Darker skin tones can show hyperpigmentation or textural change rather than bright erythema, so grading should not rely on redness alone.

Modern supportive-care guidance rejects the historical advice to avoid washing. Patients can gently wash the treated area with lukewarm water and mild fragrance-free cleanser, pat dry, and use appropriate moisturizers. Deodorant use is generally acceptable unless it irritates the skin or interferes with a specific treatment technique. Topical corticosteroids have evidence for reducing severity of acute radiation dermatitis in selected patients, and MASCC issued updated clinical practice guidance in 2026 on their preventive and management use. Barrier films such as Mepitel Film or Hydrofilm have evidence in selected breast and head-and-neck settings and now have MASCC practice guidance.

Moist desquamation requires a wound-care approach: gentle cleansing, nonadherent or moisture-balancing dressings, pain control, and monitoring for infection. Silver-containing dressings can be useful in selected weeping wounds when microbial burden is a concern, but prophylactic antibiotics are not routinely indicated. The radiation team should review field location and dose before any topical product that contains metals or thick layers is applied immediately before treatment because institutional machine and bolus policies differ.

Late skin effects include telangiectasia, fibrosis, pigment change, atrophy, poor wound healing, and rare secondary malignancy. Acute-care strategies reduce symptoms but do not eliminate all late effects. Persistent nonhealing ulceration requires specialist evaluation rather than repeated empiric creams.

Treatment Strategy & Disposition

Prevention begins on the first treatment day. Patients should use gentle cleanser, moisturize regularly with a fragrance-free product accepted by the radiation clinic, avoid scratching, minimize friction from clothing, and protect irradiated skin from excessive sun exposure. A medium-potency topical corticosteroid such as mometasone or another evidence-supported agent can be used prophylactically in selected patients according to local protocol, especially in sites with higher expected dermatitis risk. Application timing should follow the department's policy.

Grade 1 dermatitis usually needs moisturization and symptom control. Dry desquamation can benefit from emollients and topical steroid if appropriate. Moist desquamation requires nonadherent dressings, absorptive or hydrogel/hydrofiber strategies based on exudate, and adequate analgesia. Treatment interruptions are generally avoided because prolonged overall treatment time can compromise tumor control in some cancers; a break is reserved for severe toxicity when safe treatment cannot continue.

Suspected infection should be assessed clinically rather than presumed from erythema alone. Purulence, expanding warmth, fever, or systemic symptoms can justify culture and antibiotics. Severe pain out of proportion, rapidly progressive tissue injury, or ulceration beyond the expected field demands reassessment.

After radiation ends, the reaction can worsen briefly before healing because basal-cell injury continues to manifest. Patients need anticipatory guidance that peak symptoms may occur one to two weeks after treatment completion. Long-term moisturization and sun protection support skin comfort, while lymphedema, fibrosis, and restricted range of motion may need rehabilitation.

Epidemiology / Risk Factors

• Most patients receiving conventionally fractionated breast, head-and-neck, anal, vulvar, or other superficial-field radiation develop some degree of dermatitis.
• Moist desquamation is more common in folds and high-surface-dose regions.
• Concurrent systemic therapy can increase severity.
• Modern planning and skin-sparing techniques reduce severe reactions but do not eliminate them.
• Patient-reported pain and burning can be clinically significant even when visual grading appears modest.

Investigations

Do and Do Not

Pharmacology

Prognosis / Complications

• Most acute radiation dermatitis heals within several weeks after treatment.
• Severe moist desquamation can increase pain, infection risk, and treatment burden but usually re-epithelializes.
• Treatment interruptions can affect cancer outcomes in time-sensitive disease, so supportive care aims to keep therapy on schedule.
• Late fibrosis and pigment changes can persist despite acute healing.
• Rare chronic ulcers require specialist wound, surgical, or hyperbaric assessment depending on cause.

Patient Education / Counseling

• Wash gently with lukewarm water and mild fragrance-free cleanser and pat dry.
• Moisturize several times daily using products approved by the radiation clinic.
• Wear soft loose clothing and minimize rubbing in the field.
• Protect treated skin from sun and use long-term sun protection after healing.
• Report blistering, weeping skin, uncontrolled pain, fever, foul drainage, or rapidly spreading redness.
• Expect the skin reaction to peak shortly after radiation ends before it improves.
• Follow the clinic's timing instructions for creams and dressings on treatment days.

Notes

MASCC's oncodermatology group published international recommendations on acute radiation dermatitis in 2023, barrier-film guidance in 2025, and a 2026 clinical practice statement on topical corticosteroids. These updates support proactive rather than purely reactive skin care.

Different radiation departments have specific rules about when creams, powders, dressings, and deodorants can be present before treatment. The patient's own treatment team should therefore provide final product and timing instructions, especially when bolus is intentionally used.

Radiation recall dermatitis is a different phenomenon in which a systemic drug triggers inflammation in a previously irradiated field after radiation has ended. It should not be confused with expected acute dermatitis during a course of RT.

References

1. MASCC Guidelines and Clinical Practice Statements on Acute Radiation Dermatitis — Link
2. MASCC Oncodermatology Publications — Link